RAMPS VS SRPS for Pancreatic Body and Tail Adenocarcinoma
NCT04253847 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 224
Last updated 2020-02-05
Summary
Two arms RCT is design, patients with pancreatic body or tail adenocarcinoma will be randomly assigned to the Radical Antegrade Modular Pancreaticosplenectomy (RAMPS) group or Standard Retrograde Pancreatosplenectomy (SRPS) group. The primary objective is to evaluate the effect of RAMPS on the overall survival of patients with resectable body and tail pancreatic ductal adenocarcinoma. And the secondary objective is to evaluate the disease-free survival, R0 resection rate, number of retrieved lymph nodes and perioperative outcomes like postoperative complication rate, severe complications, mortality and functional recovery time between the experimental group and control group.
Conditions
- Radical Antegrade Modular Pancreatosplenectomy
Interventions
- PROCEDURE
-
Radical antegrade modular pancreatosplenectomy
Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is "antegrade", which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called "posterior approach RAMPS". While in normal cases, left adrenal gland will be preserved.
- PROCEDURE
-
Standard retrograde pancreatosplenectomy
Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is "retrograde", which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved.
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-15
- Primary Completion
- 2022-02-28
- Completion
- 2027-02-28
Countries
- China
Study Locations
More Related Trials
-
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
NCT06914674 ·Status: RECRUITING ·Phase: PHASE2
-
Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?
NCT02787187 ·Status: COMPLETED ·Phase: NA
-
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
NCT04603586 ·Status: COMPLETED ·Phase: NA
-
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
NCT05083247 ·Status: RECRUITING ·Phase: PHASE2
-
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
NCT04855331 ·Status: RECRUITING ·Phase: NA
-
Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis
NCT03524677 ·Status: UNKNOWN
-
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
NCT06913218 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
NCT05482451 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
NCT04089150 ·Status: UNKNOWN ·Phase: PHASE2
-
Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors
NCT01412684 ·Status: WITHDRAWN
-
Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
NCT04699539 ·Status: COMPLETED ·Phase: NA
-
A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05969171 ·Status: RECRUITING ·Phase: PHASE2
-
Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer
NCT02981719 ·Status: COMPLETED ·Phase: NA
-
Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer
NCT02745847 ·Status: UNKNOWN ·Phase: NA
-
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06389760 ·Status: RECRUITING ·Phase: PHASE2
-
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
NCT02928081 ·Status: UNKNOWN ·Phase: NA
-
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
NCT06404840 ·Status: RECRUITING ·Phase: PHASE2
-
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
NCT04581876 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
NCT04498689 ·Status: UNKNOWN ·Phase: PHASE2
-
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
NCT05832892 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064 ·Status: UNKNOWN ·Phase: PHASE3
-
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
NCT07105852 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)
NCT02461836 ·Status: UNKNOWN ·Phase: PHASE2
-
Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT)
NCT02081131 ·Status: COMPLETED ·Phase: NA
-
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
NCT02506842 ·Status: UNKNOWN ·Phase: PHASE3